Invention Grant
- Patent Title: Bispecific anti-IGF-1R and anti-ErbB3 antibodies
- Patent Title (中): 双特异性抗IGF-1R和抗ErbB3抗体
-
Application No.: US13451135Application Date: 2012-04-19
-
Publication No.: US08476409B2Publication Date: 2013-07-02
- Inventor: Jason Baum , Bryan Johnson , Alexey Alexandrovich Lugovskoy , Lihui Xu , Neeraj Kohli , Jonathan Basil Fitzgerald , Sharlene Adams
- Applicant: Jason Baum , Bryan Johnson , Alexey Alexandrovich Lugovskoy , Lihui Xu , Neeraj Kohli , Jonathan Basil Fitzgerald , Sharlene Adams
- Applicant Address: US MA Cambridge
- Assignee: Merrimack Pharmaceuticals, Inc.
- Current Assignee: Merrimack Pharmaceuticals, Inc.
- Current Assignee Address: US MA Cambridge
- Agency: Lathrop & Gage LLP
- Agent James H. Velema, Esq.
- Main IPC: C07K16/30
- IPC: C07K16/30 ; C07H21/04 ; A61K39/00
Abstract:
Provided are bispecific antibodies that are useful as anti-neoplastic agents and that bind specifically to human IGF-1R and human ErbB3. Exemplary antibodies inhibit signal transduction through either or both of IGF-1R and ErbB3.
Public/Granted literature
- US20120269812A1 MONOSPECIFIC AND BISPECIFIC ANTI-IGF-1R AND ANTI-ERBB3 ANTIBODIES Public/Granted day:2012-10-25
Information query
